Genscript Biotech Stock Cash And Equivalents
| GNNSF Stock | USD 1.36 0.11 8.80% |
Genscript Biotech fundamentals help investors to digest information that contributes to Genscript Biotech's financial success or failures. It also enables traders to predict the movement of Genscript Pink Sheet. The fundamental analysis module provides a way to measure Genscript Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genscript Biotech pink sheet.
Genscript |
Genscript Biotech Company Cash And Equivalents Analysis
Genscript Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Genscript Biotech Cash And Equivalents | 1.26 B |
Most of Genscript Biotech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genscript Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Genscript Biotech has 1.26 B in Cash And Equivalents. This is 53.49% higher than that of the Healthcare sector and 181.8% higher than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 53.37% higher than that of the company.
Genscript Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genscript Biotech's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genscript Biotech could also be used in its relative valuation, which is a method of valuing Genscript Biotech by comparing valuation metrics of similar companies.Genscript Biotech is currently under evaluation in cash and equivalents category among its peers.
Genscript Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.66) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 5.11 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 38.31 % | |||
| Shares Owned By Institutions | 24.68 % | |||
| Price To Earning | 200.00 X | |||
| Price To Book | 6.65 X | |||
| Price To Sales | 10.82 X | |||
| Revenue | 510.6 M | |||
| Gross Profit | 303.48 M | |||
| EBITDA | (494 M) | |||
| Net Income | (347.87 M) | |||
| Cash And Equivalents | 1.26 B | |||
| Cash Per Share | 0.60 X | |||
| Total Debt | 121.07 M | |||
| Debt To Equity | 0.56 % | |||
| Current Ratio | 2.92 X | |||
| Book Value Per Share | 0.36 X | |||
| Cash Flow From Operations | (136.79 M) | |||
| Earnings Per Share | (0.17) X | |||
| Number Of Employees | 5.57 K | |||
| Beta | 1.35 | |||
| Market Capitalization | 6.67 B | |||
| Total Asset | 2.23 B | |||
| Z Score | 33.0 | |||
| Net Asset | 2.23 B |
About Genscript Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genscript Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genscript Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genscript Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.